Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant-Ineligible Newly Diagnosed Myeloma: An Australian Real-World, Multicenter Study - PubMed
4 hours ago
- #multiple myeloma
- #RVD regimen
- #transplant-ineligible
- Study evaluates efficacy and tolerability of weekly bortezomib, lenalidomide, and dexamethasone (RVD) in transplant-ineligible newly diagnosed myeloma patients in Australia.
- Two modified RVD regimens (Modified SWOG and Modified RVD Lite) were assessed, showing high overall response rates (ORR) and very good partial response (≥VGPR) rates.
- Modified SWOG achieved ORR of 91.4% and ≥VGPR of 71.4%, with 24-month PFS of 63.1%.
- Modified RVD Lite achieved ORR of 93.9% and ≥VGPR of 64.7%, with 24-month PFS of 53.6%.
- Despite dose adjustments, significant toxicity was observed, including hospitalizations in 48.2% and treatment cessation due to toxicity in 31.3%.
- Peripheral sensory neuropathy was reported in 38.6% of patients, with only 2 cases of Grade 3 severity.
- Findings suggest weekly RVD regimens have comparable efficacy to twice-weekly regimens but toxicity remains a challenge in transplant-ineligible patients.